Caveolin-1 Regulates CCL5 and PPARγ Expression in Nthy-ori 3-1 Cells: Possible Involvement of Caveolin-1 and CCL5 in the Pathogenesis of Hashimoto's Thyroiditis

Endocr Metab Immune Disord Drug Targets. 2020;20(4):609-618. doi: 10.2174/1871530319666191202115149.

Abstract

Background: Hashimoto's thyroiditis (HT) is characterized by lymphocytic infiltration of the thyroid parenchyma, which ultimately leads to tissue destruction and loss of function. Caveolin-1 (Cav-1) is an essential structural constituent of lipid rafts in the plasma membrane of cells and is reported to be significantly reduced in thyrocytes from HT patients. However, the mechanism of Cav-1 involvement in HT pathogenesis is still largely unclear.

Methods: Cav-1 expression in thyroid tissues from HT patients and euthyroid nodular goiter tissues was detected by immunohistochemistry staining. Cav-1 knockdown and overexpression were constructed by lentiviral transfection in the human thyroid follicular epithelial cell (TFC) line of Nthy-ori 3-1. The mRNA expression levels of chemokines in TFCs were determined by quantitative real-time PCR (qPCR). Cav-1 and peroxisome proliferator-activated receptor gamma (PPARγ) levels were analysed by qPCR and Western blot analysis. The migration ability of peripheral blood mononuclear cells (PBMCs) was detected by the Transwell assay.

Results: In this study, Cav-1 and PPARγ expression was reduced in the thyroid tissues from HT patients. In vitro experiments showed that the expressions of chemokine (C-C motif) ligand 5 (CCL5) and migration of PBMCs were markedly increased, while the level of PPARγ was significantly decreased after the lentivirus-mediated knockdown of Cav-1 in Nthy-ori 3-1 cells. Interestingly, pioglitazone, a PPARγ agonist, not only upregulated PPARγ and Cav-1 proteins significantly, but also effectively reversed the Cav-1-knockdown-induced upregulation of CCL5 in Nthy-ori 3-1 cells and reduced the infiltration of lymphocytes.

Conclusion: The inhibition of Cav-1 upregulated the CCL5 expression and downregulated the PPARγ expression in TFC while pioglitazone, a PPARγ agonist, reversed the detrimental consequence. This outcome might be a potential target for the treatment of lymphocyte infiltration into the thyroid gland and HT development.

Keywords: CCL5; Cav-1; Chemokine; Hashimoto’s thyroiditis; PPARγ; Pioglitazone..

MeSH terms

  • Caveolin 1 / biosynthesis*
  • Caveolin 1 / genetics
  • Cell Line
  • Cell Movement / drug effects
  • Cell Movement / physiology
  • Chemokine CCL5 / biosynthesis*
  • Chemokine CCL5 / genetics
  • Gene Expression
  • Hashimoto Disease / genetics
  • Hashimoto Disease / metabolism*
  • Hashimoto Disease / pathology
  • Humans
  • PPAR gamma / agonists
  • PPAR gamma / biosynthesis*
  • PPAR gamma / genetics
  • Pioglitazone / pharmacology
  • Thyroid Gland / drug effects
  • Thyroid Gland / metabolism

Substances

  • CAV1 protein, human
  • CCL5 protein, human
  • Caveolin 1
  • Chemokine CCL5
  • PPAR gamma
  • Pioglitazone